Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.


Journal

mSphere
ISSN: 2379-5042
Titre abrégé: mSphere
Pays: United States
ID NLM: 101674533

Informations de publication

Date de publication:
31 08 2022
Historique:
pubmed: 22 7 2022
medline: 9 9 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 and has resulted in millions of deaths worldwide. Certain populations are at higher risk for infection, especially staff and residents at long-term care facilities (LTCF), due to the congregant living setting and high proportions of residents with many comorbidities. Prior to vaccine availability, these populations represented large fractions of total coronavirus disease 2019 (COVID-19) cases and deaths in the United States. Due to the high-risk setting and outbreak potential, staff and residents were among the first groups to be vaccinated. To define the impact of prior infection on the response to vaccination, we measured antibody responses in a cohort of staff members at an LTCF, many of whom were previously infected by SARS-CoV-2. We found that neutralizing, receptor-binding domain (RBD)-binding, and nucleoprotein (NP)-binding antibody levels were significantly higher after the full vaccination course in individuals that were previously infected and that NP antibody levels could discriminate individuals with prior infection from vaccinated individuals. While an anticipated antibody titer increase was observed after a vaccine booster dose in naive individuals, a boost response was not observed in individuals with previous COVID-19 infection. We observed a strong relationship between neutralizing antibodies and RBD-binding antibodies postvaccination across all groups, whereas no relationship was observed between NP-binding and neutralizing antibodies. One individual with high levels of neutralizing and binding antibodies experienced a breakthrough infection (prior to the introduction of Omicron), demonstrating that the presence of antibodies is not always sufficient for complete protection against infection. These results highlight that a history of COVID-19 exposure significantly increases SARS-CoV-2 antibody responses following vaccination.

Identifiants

pubmed: 35862798
doi: 10.1128/msphere.00169-22
pmc: PMC9429942
doi:

Substances chimiques

Antibodies, Neutralizing 0
Antibodies, Viral 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0016922

Références

JAMA. 2022 Feb 15;327(7):639-651
pubmed: 35060999
Front Immunol. 2022 Jan 03;12:775420
pubmed: 35046939
Nat Commun. 2021 Nov 4;12(1):6379
pubmed: 34737312
EBioMedicine. 2021 Jun;68:103401
pubmed: 34051441
BMC Med. 2021 Jul 26;19(1):169
pubmed: 34304742
J Virol. 2021 Jan 13;95(3):
pubmed: 33144321
Nature. 2021 Jan;589(7841):182
pubmed: 33437062
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Microbiol Spectr. 2021 Dec 22;9(3):e0100321
pubmed: 34756092
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
N Engl J Med. 2021 Feb 18;384(7):e23
pubmed: 33406324
Viruses. 2021 Dec 28;14(1):
pubmed: 35062247
BMC Med. 2020 Dec 8;18(1):386
pubmed: 33287821
EClinicalMedicine. 2021 Aug;38:101018
pubmed: 34278286
Cell Host Microbe. 2022 Mar 9;30(3):400-408.e4
pubmed: 35134333
EBioMedicine. 2022 Jan;75:103805
pubmed: 35032961
J Am Geriatr Soc. 2020 Oct;68(10):2153-2162
pubmed: 32735036
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Nature. 2021 Jan;589(7841):169-170
pubmed: 33437064
Nature. 2022 Feb 2;:
pubmed: 35106008
J Am Med Dir Assoc. 2020 Dec;21(12):1767-1773.e1
pubmed: 33153910
Nat Commun. 2021 Oct 15;12(1):6032
pubmed: 34654808
Lancet Respir Med. 2022 Feb;10(2):e17
pubmed: 34929158
Ann Rheum Dis. 2022 Jun;81(6):868-874
pubmed: 35135831
Nat Rev Immunol. 2020 Aug;20(8):457-458
pubmed: 32636479
Microbiol Spectr. 2021 Sep 3;9(1):e0022421
pubmed: 34287058
Front Immunol. 2022 Jan 25;13:816220
pubmed: 35145522
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Vaccine. 2022 Apr 1;40(15):2251-2257
pubmed: 35287986
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
J Med Virol. 2022 Apr;94(4):1336-1349
pubmed: 34845731
Nature. 2021 Jul;595(7866):161-162
pubmed: 34176923
BMC Infect Dis. 2022 Jan 29;22(1):105
pubmed: 35093012
Science. 2021 Mar 25;:
pubmed: 33766944
Sci Transl Med. 2022 Mar 23;14(637):eabn8057
pubmed: 35166573
NPJ Vaccines. 2021 Nov 4;6(1):132
pubmed: 34737318

Auteurs

Emily N Gallichotte (EN)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Mary Nehring (M)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Sophia Stromberg (S)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Michael C Young (MC)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Ashley Snell (A)

Columbine Health Systems Center for Healthy Aging, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Josh Daniels (J)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Kristy L Pabilonia (KL)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Sue VandeWoude (S)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Nicole Ehrhart (N)

Columbine Health Systems Center for Healthy Aging, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.
Department of Clinical Sciences, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Gregory D Ebel (GD)

Department of Microbiology, Immunology and Pathology, Colorado State Universitygrid.47894.36, Fort Collins, Colorado, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH